Denali Therapeutics Reports Positive Clinical Data Across Three Lysosomal Storage Disorder Programs
Event summary
- Denali Therapeutics presented clinical data for three lysosomal storage disorder programs at the 2026 WORLDSymposium™, highlighting progress in Hunter syndrome, Sanfilippo syndrome type A, and Pompe disease.
- Tividenofusp alfa (DNL310) for Hunter syndrome showed sustained biomarker reductions and clinical improvements through Week 201, with a PDUFA decision date of April 5, 2026.
- DNL126 (ETV:SGSH) for Sanfilippo syndrome type A demonstrated an 80% mean reduction in CSF heparan sulfate and a generally consistent safety profile with established ERTs.
- Denali presented the Phase 1 clinical study design for DNL952 (ETV:GAA) for Pompe disease, with preclinical data showing improved glycogen reduction in muscle and brain.
The big picture
Denali Therapeutics is advancing its Enzyme TransportVehicle™ platform to address critical unmet needs in lysosomal storage disorders, positioning itself as a leader in brain-penetrant enzyme replacement therapies. The company's strategic focus on rare diseases with significant neurological components aligns with broader industry trends towards targeted therapies for complex genetic disorders. Success in these programs could validate Denali's technology platform and drive long-term growth.
What we're watching
- Regulatory Approval
- Whether the FDA will approve tividenofusp alfa for Hunter syndrome by the April 5, 2026 PDUFA date, which would mark a significant milestone for Denali's Enzyme TransportVehicle™ platform.
- Clinical Development
- The pace at which Denali can advance DNL126 for Sanfilippo syndrome type A towards a BLA submission and potential approval in 2027, following the FDA's alignment on CSF HS as a surrogate endpoint.
- Pipeline Expansion
- How Denali's progress in Pompe disease with DNL952 will impact its pipeline diversification and potential market opportunities in muscle and nervous system manifestations.
Related topics